LISATA THERAPEUTICS, INC. 8-K

What Happened
Lisata Therapeutics, Inc. (LSTA) announced that Kuva Labs Inc. (Parent) and its wholly owned subsidiary Kuva Acquisition Corp. (Purchaser) agreed to extend the date by which Purchaser must commence the tender offer under the March 6, 2026 Merger Agreement. The start date was extended from April 3, 2026, to April 13, 2026 (or another date if agreed by the parties). A signed waiver to the Merger Agreement dated April 2, 2026 is attached as Exhibit 99.1 to the 8-K. The tender offer has not yet commenced.

Key Details

• Parties: Lisata Therapeutics, Kuva Labs Inc. (Parent) and Kuva Acquisition Corp. (Purchaser).
• Agreement date: Merger Agreement dated March 6, 2026; waiver dated April 2, 2026.
• New commencement deadline: extended from April 3, 2026 to April 13, 2026 (or other mutually agreed date).
• Regulatory filings: Parent/Purchaser will file a Schedule TO and Lisata will file a Schedule 14D-9 when the tender offer is commenced; offer materials will be made available free to stockholders and on the SEC website.

Why It Matters
The extension changes the timetable for the proposed acquisition and gives the parties additional time before the formal tender offer begins. For shareholders, this means the formal offer materials (Schedule TO and Lisata’s Schedule 14D-9) — which will contain the full terms, risks and Lisata’s recommendation — are not yet available; investors should review those documents when filed. The company’s 8-K also highlights forward-looking risks in the transaction (including timing, shareholder tendering uncertainty, competing offers, potential termination events, CVR milestone uncertainty, litigation risk, and usual clinical/commercial uncertainties) that could affect the outcome.